Cystic Fibrosis Foundation
Posted on by Dr. Francis Collins
Happy New Year! As we say goodbye to the Teens, let’s take a look back at 2019 and some of the groundbreaking scientific discoveries that closed out this remarkable decade.
Each December, the reporters and editors at the journal Science select their breakthrough of the year, and the choice for 2019 is nothing less than spectacular: An international network of radio astronomers published the first image of a black hole, the long-theorized cosmic singularity where gravity is so strong that even light cannot escape . This one resides in a galaxy 53 million light-years from Earth! (A light-year equals about 6 trillion miles.)
Though the competition was certainly stiff in 2019, the biomedical sciences were well represented among Science’s “runner-up” breakthroughs. They include three breakthroughs that have received NIH support. Let’s take a look at them:
In a first, drug treats most cases of cystic fibrosis: Last October, two international research teams reported the results from phase 3 clinical trials of the triple drug therapy Trikafta to treat cystic fibrosis (CF). Their data showed Trikafta effectively compensates for the effects of a mutation carried by about 90 percent of people born with CF. Upon reviewing these impressive data, the Food and Drug Administration (FDA) approved Trikafta, developed by Vertex Pharmaceuticals.
The approval of Trikafta was a wonderful day for me personally, having co-led the team that isolated the CF gene 30 years ago. A few years later, I wrote a song called “Dare to Dream” imagining that wonderful day when “the story of CF is history.” Though we’ve still got more work to do, we’re getting a lot closer to making that dream come true. Indeed, with the approval of Trikafta, most people with CF have for the first time ever a real chance at managing this genetic disease as a chronic condition over the course of their lives. That’s a tremendous accomplishment considering that few with CF lived beyond their teens as recently as the 1980s.
Such progress has been made possible by decades of work involving a vast number of researchers, many funded by NIH, as well as by more than two decades of visionary and collaborative efforts between the Cystic Fibrosis Foundation and Aurora Biosciences (now, Vertex) that built upon that fundamental knowledge of the responsible gene and its protein product. Not only did this innovative approach serve to accelerate the development of therapies for CF, it established a model that may inform efforts to develop therapies for other rare genetic diseases.
Hope for Ebola patients, at last: It was just six years ago that news of a major Ebola outbreak in West Africa sounded a global health emergency of the highest order. Ebola virus disease was then recognized as an untreatable, rapidly fatal illness for the majority of those who contracted it. Though international control efforts ultimately contained the spread of the virus in West Africa within about two years, over 28,600 cases had been confirmed leading to more than 11,000 deaths—marking the largest known Ebola outbreak in human history. Most recently, another major outbreak continues to wreak havoc in northeastern Democratic Republic of Congo (DRC), where violent civil unrest is greatly challenging public health control efforts.
As troubling as this news remains, 2019 brought a needed breakthrough for the millions of people living in areas susceptible to Ebola outbreaks. A randomized clinical trial in the DRC evaluated four different drugs for treating acutely infected individuals, including an antibody against the virus called mAb114, and a cocktail of anti-Ebola antibodies referred to as REGN-EB3. The trial’s preliminary data showed that about 70 percent of the patients who received either mAb114 or the REGN-EB3 antibody cocktail survived, compared with about half of those given either of the other two medicines.
So compelling were these preliminary results that the trial, co-sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID) and the DRC’s National Institute for Biomedical Research, was halted last August. The results were also promptly made public to help save lives and stem the latest outbreak. All Ebola patients in the DRC treatment centers now are treated with one or the other of these two options. The trial results were recently published.
The NIH-developed mAb114 antibody and the REGN-EB3 cocktail are the first therapeutics to be shown in a scientifically rigorous study to be effective at treating Ebola. This work also demonstrates that ethically sound clinical research can be conducted under difficult conditions in the midst of a disease outbreak. In fact, the halted study was named Pamoja Tulinde Maisha (PALM), which means “together save lives” in Kiswahili.
To top off the life-saving progress in 2019, the FDA just approved the first vaccine for Ebola. Called Ervebo (earlier rVSV-ZEBOV), this single-dose injectable vaccine is a non-infectious version of an animal virus that has been genetically engineered to carry a segment of a gene from the Zaire species of the Ebola virus—the virus responsible for the current DRC outbreak and the West Africa outbreak. Because the vaccine does not contain the whole Zaire virus, it can’t cause Ebola. Results from a large study in Guinea conducted by the WHO indicated that the vaccine offered substantial protection against Ebola virus disease. Ervebo, produced by Merck, has already been given to over 259,000 individuals as part of the response to the DRC outbreak. The NIH has supported numerous clinical trials of the vaccine, including an ongoing study in West Africa.
Microbes combat malnourishment: Researchers discovered a few years ago that abnormal microbial communities, or microbiomes, in the intestine appear to contribute to childhood malnutrition. An NIH-supported research team followed up on this lead with a study of kids in Bangladesh, and it published last July its groundbreaking finding: that foods formulated to repair the “gut microbiome” helped malnourished kids rebuild their health. The researchers were able to identify a network of 15 bacterial species that consistently interact in the gut microbiomes of Bangladeshi children. In this month-long study, this bacterial network helped the researchers characterize a child’s microbiome and/or its relative state of repair.
But a month isn’t long enough to determine how the new foods would help children grow and recover. The researchers are conducting a similar study that is much longer and larger. Globally, malnutrition affects an estimated 238 million children under the age 5, stunting their normal growth, compromising their health, and limiting their mental development. The hope is that these new foods and others adapted for use around the world soon will help many more kids grow up to be healthy adults.
Measles Resurgent: The staff at Science also listed their less-encouraging 2019 Breakdowns of the Year, and unfortunately the biomedical sciences made the cut with the return of measles in the U.S. Prior to 1963, when the measles vaccine was developed, 3 to 4 million Americans were sickened by measles each year. Each year about 500 children would die from measles, and many more would suffer lifelong complications. As more people were vaccinated, the incidence of measles plummeted. By the year 2000, the disease was even declared eliminated from the U.S.
But, as more parents have chosen not to vaccinate their children, driven by the now debunked claim that vaccines are connected to autism, measles has made a very preventable comeback. Last October, the Centers for Disease Control and Prevention (CDC) reported an estimated 1,250 measles cases in the United States at that point in 2019, surpassing the total number of cases reported annually in each of the past 25 years.
The good news is those numbers can be reduced if more people get the vaccine, which has been shown repeatedly in many large and rigorous studies to be safe and effective. The CDC recommends that children should receive their first dose by 12 to 15 months of age and a second dose between the ages of 4 and 6. Older people who’ve been vaccinated or have had the measles previously should consider being re-vaccinated, especially if they live in places with low vaccination rates or will be traveling to countries where measles are endemic.
Despite this public health breakdown, 2019 closed out a memorable decade of scientific discovery. The Twenties will build on discoveries made during the Teens and bring us even closer to an era of precision medicine to improve the lives of millions of Americans. So, onward to 2020—and happy New Year!
 2019 Breakthrough of the Year. Science, December 19, 2019.
NIH Support: These breakthroughs represent the culmination of years of research involving many investigators and the support of multiple NIH institutes.
Posted on by Dr. Francis Collins
When your world has been touched by a life-threatening disease, it’s hard to spend a lot of time dreaming about the future. But that’s exactly what Jenny, an 8-year-old girl with cystic fibrosis (CF), did 30 years ago upon hearing the news that I and my colleagues in Ann Arbor and Toronto had discovered the gene for CF [1,2]. Her upbeat diary entry, which you can read above, is among the many ways in which people with CF have encouraged researchers on the long and difficult road toward achieving our shared dream of effective, molecularly targeted therapies for one of the nation’s most common potentially fatal recessive genetic diseases, affecting more than 30,000 individuals in the United States .
Today, I’m overjoyed to say that this dream finally appears to have come true for about 90 percent of people with CF. In papers in the New England Journal of Medicine and The Lancet [4,5], two international teams, including researchers partly supported by NIH, report impressive results from phase 3 clinical trials of a triple drug therapy for individuals with CF and at least one copy of Phe508del, the most common CF-causing mutation. And Jenny happens to be among those who now stand to benefit from this major advance.
Now happily married and living in Colorado, Jenny is leading an active life, writing a children’s book and trying to keep up with her daughter Pippa Lou, whom you see with her in the photo above. In a recent email to me, her optimistic outlook continues to shine through: “I have ALWAYS known in my heart that CF will be cured during my lifetime and I have made it my goal to be strong and ready for that day when it comes. None of the advancements in care would be what they are without you.”
But there are a great many more people who need to be recognized and thanked. Such advances were made possible by decades of work involving a vast number of other researchers, many funded by NIH, as well as by more than two decades of visionary and collaborative efforts between the Cystic Fibrosis Foundation and Aurora Biosciences (now, Vertex Pharmaceuticals) that built upon that fundamental knowledge of the responsible gene and its protein product. Not only did this innovative approach serve to accelerate the development of therapies for CF, it established a model that may inform efforts to develop therapies for other rare genetic diseases.
To understand how the new triple therapy works, one first needs to understand some things about the protein affected by CF, the cystic fibrosis transmembrane regulator (CFTR). In healthy people, CFTR serves as a gated channel for chloride ions in the cell membrane, regulating the balance of salt and water in the lungs, pancreas, sweat glands, and other organ systems.
People with the most common CF-causing Phe508del mutation produce a CFTR protein with two serious problems: misfolding that often results in the protein becoming trapped in the cell’s factory production line called the endoplasmic reticulum; and deficient activation of any protein that does manage to reach its proper location in the cell membrane. Consequently, an effective therapy for such people needs to include drugs that can correct the CFTR misfolding, along with those than can activate, or potentiate, the function of CFTR when it reaches the cell membrane.
The new triple combination therapy, which was developed by Vertex Pharmaceuticals and recently approved by the Food and Drug Administration (FDA) , is elexacaftor-tezacaftor-ivacaftor (two correctors and one potentiator). This approach builds upon the success of ivacaftor monotherapy, approved by the FDA in 2012 for rare CF-causing mutations; and tezacaftor-ivacaftor dual therapy, approved by the FDA in 2018 for people with two copies of the Phe508del mutation.
Specifically, the final results from two Phase 3 multi-center, randomized clinical trials demonstrated the safety and efficacy of the triple combination therapy for people with either one or two copies of the Phe508del mutation—which represents about 90 percent of people with CF. Patients in both trials experienced striking improvements in a key measure of lung capacity (forced expiratory volume in 1 second) and in sweat chloride levels, which show if the drugs are working throughout the body. In addition, the triple therapy was generally safe and well tolerated, with less than 1 percent of patients discontinuing the treatment due to adverse effects.
This is wonderful news! But let’s be clear—we are not yet at our journey’s end when it comes to realizing the full dream of defeating CF. More work remains to be done to help the approximately 10 percent of CF patients whose mutations result in the production of virtually no CFTR protein, which means there is nothing for current drugs to correct or activate.
Beyond that, wouldn’t it be great if biomedical science could figure out a way to permanently cure CF, perhaps using nonheritable gene editing, so no one needs to take drugs at all? It’s a bold dream, but look how far a little dreaming, plus a lot of hard work, has taken us so far in Jenny’s life.
In closing, I’d like to leave you with the chorus of a song, called “Dare to Dream,” that I wrote shortly after we identified the CF gene. I hope the words inspire not only folks affected by CF, but everyone who is looking to NIH-supported research for healing and hope.
Dare to dream, dare to dream,
All our brothers and sisters breathing free.
Unafraid, our hearts unswayed,
‘Til the story of CF is history.
. Identification of the cystic fibrosis gene: chromosome walking and jumping. Rommens JM, Iannuzzi MC, Kerem B, et al. Science 1989; 245:1059-1065.
. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Riordan JR, Rommens JM, Kerem B, et al. Science 1989; 245:1066-73. Erratum in: Science 1989; 245:1437.
 Realizing the Dream of Molecularly Targeted Therapies for Cystic Fibrosis. Collins, FS. N Engl J Med. 2019 Oct 31. [Epub ahead of print]
. Elexacaftor-Tezacaftor-Ivacaftor for CF with a Single Phe508del Mutation. Middleton P, Mall M, Drevinek P, et al.N Engl J Med. 2019 Oct 31. [Epub ahead of print]
 Efficacy and safety of the elexacaftor/tezacaftor/ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial. Heijerman H, McKone E, Downey D, et al. Lancet. 2019 Oct 31. [Epub ahead of print]
 FDA approves new breakthrough therapy for cystic fibrosis. FDA News Release, Oct. 21, 2019.
Cystic Fibrosis (Genetics Home Reference/National Library of Medicine/NIH)
Research Milestones (Cystic Fibrosis Foundation, Bethesda, MD)
Wheezie Stevens in “Bubbles Can’t Hold Rain,” by Jennifer K. McGlincy
NIH Support: National, Heart, Lung and Blood Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Center for Advancing Translational Sciences
Posted on by Dr. Francis Collins
As NIH Director, I often hear stories of how people with serious diseases—from arthritis to Zika infection—are benefitting from the transformational power of NIH’s investments in basic science. Today, I’d like to share one such advance that I find particularly exciting: news that a combination of three molecularly targeted drugs may finally make it possible to treat the vast majority of patients with cystic fibrosis (CF), our nation’s most common genetic disease.
First, a bit of history! The first genetic mutation that causes CF was discovered by a collaborative effort between my own research lab at the University of Michigan, Ann Arbor, and colleagues at the Hospital for Sick Children in Toronto—more than 25 years ago . Years of hard work, supported by the National Institutes of Health and the Cystic Fibrosis Foundation, painstakingly worked out the normal function of the protein that is altered in CF, called the cystic fibrosis transmembrane regulator (CFTR). Very recently new technologies, such as cryo-EM, have given researchers the ability to map the exact structure of the protein involved in CF.
Among the tens of thousands of CF patients who stand to benefit from the next generation of targeted drugs is little Avalyn Mahoney of Cardiff by the Sea, CA. Just a few decades ago, a kid like Avalyn—who just turned 2 last month—probably wouldn’t have made it beyond her teens. But today the outlook is far brighter for her and so many others, thanks to recent advances that build upon NIH-supported basic research.
Posted on by Dr. Francis Collins
It’s been more than a quarter-century since my colleagues and I were able to identify the gene responsible for cystic fibrosis (CF), a life-shortening inherited disease that mainly affects the lungs and pancreas . And, at a recent event in New York, I had an opportunity to celebrate how far we’ve come since then in treating CF, as well as to honor a major force behind that progress, Dr. Bob Beall, who has just retired as president and chief executive officer of the Cystic Fibrosis Foundation.
Thanks to the tireless efforts of Bob and many others in the public and private sectors to support basic, translational, and clinical research, we today have two therapies from Vertex Pharmaceuticals that are targeted specifically at CF’s underlying molecular cause: ivacaftor (Kalydeco™), approved by the Food and Drug Administration (FDA) in 2012 for people with an uncommon mutation in the CF gene; and the combination ivacaftor-lumacaftor (Orkambi™), approved by the FDA in July for the roughly 50 percent of CF patients with two copies of the most common mutation. Yet more remains to be done before we can truly declare victory. Not only are new therapies needed for people with other CF mutations, but also for those with the common mutation who don’t respond well to Orkambi™. So, the work needs to go on, and I’m encouraged by new findings that suggest a different strategy for helping folks with the most common CF mutation.